<DOC>
	<DOCNO>NCT01209442</DOCNO>
	<brief_summary>The purpose study find whether Hypofractionated Intensity-Modulated Radiation Therapy ( Hypo-IMRT ) combine temozolomide chemotherapy safely give targeted agent , bevacizumab , effective study treatment control brain tumor .</brief_summary>
	<brief_title>Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide Bevacizumab Glioblastoma Multiforme</brief_title>
	<detailed_description>This pilot phase II trial combination concurrent hypofractionated IMRT ( 60 Gy/2 week ) , temozolomide bevacizumab follow 6 cycle adjuvant bevacizumab temozolomide patient grade IV malignant glioma ( glioblastoma gliosarcoma ) . The study survival toxicity endpoint .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically confirm diagnosis WHO grade IV primary malignant glioma ( GBM gliosarcoma ) . Age ≥ 18 year time study registration Karnofsky Performance Scale ≥ 60 % Absolute Neutrophil Count ( ANC ) ≥ 1,500 cells/mm3 , hemoglobin ≥ 9.0 g/dl , platelet ≥ 100,000 cells/ mm3 Serum creatinine ≤ 1.5 mg/dl , serum glutamate oxaloacetate transaminase ( SGOT ) bilirubin ≤ 1.5 time upper limit normal Signed inform consent approve Institutional Review Board Craniotomy intracranial biopsy site must adequately heal , free drainage cellulitis , underlie cranioplasty must appear intact time study entry . Study treatment initiate &gt; 28 day follow last surgical procedure ( include open biopsy , surgical resection , wound revision , major surgery involve entry body cavity ) Life expectancy le 12 week Prior treatment , include radiation therapy chemotherapy , GBM exception surgery ( Gliadel Wafers allow time surgery ) Active malignancy , exception superficial basal cell and/or superficial squamous ( skin ) cell , carcinoma situ cervix Active infection require IV antibiotic Pregnant breast feed International normalized ratio ( INR ) &gt; 1.5 activate partial thromboplastin time ( aPTT ) &gt; 1.5 × upper limit normal ( ULN ) ( except subject receive anticoagulation therapy ) absence therapeutic intent anticoagulate subject . Therapeutic anticoagulation permit Evidence ≥ Common Toxicity Criteria Adverse Effects ( CTCAE ) v.3 grade 2 CNS hemorrhage ( CNS hemorrhage medical intervention indicate ) , grade 1 CNS hemorrhage ( asymptomatic radiographic finding baseline brain CT MRI ) allow . Punctate hemorrhage presence hemosiderin consider Grade 1 event purpose study . ) Inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) Prior history hypertensive crisis hypertensive encephalopathy Current New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction unstable angina within 6 month prior enrollment History stroke transient ischemic attack within 6 month prior enrollment Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior enrollment History hemoptysis ( ≥ 1/2 teaspoon bright red blood per episode ) within 1 month prior enrollment Evidence bleeding diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior enrollment anticipation need major surgical procedure course study Core needle biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior enrollment History abdominal fistula gastrointestinal perforation within 6 month prior enrollment Serious , nonhealing wound , active ulcer , untreated bone fracture Proteinuria demonstrate Urine proteincreatinine ratio ( UPC ) ratio ≥ 1.0 screening ( Appendix A ) . Known hypersensitivity component bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Multiforme</keyword>
</DOC>